ME

MKT CAP:$15M

23andMe Holding Co.

Market Cap

$15M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$0.61+$0.00 (+0.00%)

Mar 19, 2026

Company Details

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including in...

CEO

Joseph Selsavage

IPO Date

Nov 23, 2020

Website

www.23andme.com

Key Metrics TTM

Revenue

$175M

-12.2% YoY

Net Income

-$235M

EPS (Diluted)

-$9.05

Free Cash Flow

-$161M

Revenue / Share

$6.36

Gross Margin

53.3%

Operating Margin

-114.0%

Net Margin

-134.5%

FCF Margin

-92.0%

P/S

0.1x

P/E

—

Earnings Reports

FY 2025

Aug 4, 2025

$25M-86.6%EPS -$0.87

Q1 2025

Aug 4, 2025

$25M-37.1%EPS -$0.87

FY 2024

Jun 11, 2025

$190M-13.5%EPS -$10.98

Q4 2024

Jun 11, 2025

$45M-29.5%EPS -$3.85

Q3 2024

Feb 6, 2025

$60M+34.7%EPS -$2.01

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 21	$55M	$28M	-$46M
Q3 21	$57M	$27M	-$97M
Q4 21	$101M	$47M	-$69M
Q1 22	$65M	$25M	-$90M
Q2 22	$76M	$38M	-$68M
Q3 22	$67M	$31M	-$97M
Q4 22	$92M	$40M	-$69M
Q1 23	$61M	$31M	-$109M
Q2 23	$50M	$22M	-$79M
Q3 23	$45M	$20M	-$81M
Q4 23	$64M	$27M	-$59M
Q1 24	$40M	$21M	-$72M
Q2 24	$44M	$22M	-$61M
Q3 24	$60M	$40M	-$9M
Q4 24	$45M	$18M	-$99M
Q1 25	$25M	$14M	-$31M

Valuation

Quarter	P/S	P/E
Q2 21	0.1x	—
Q3 21	0.1x	—
Q4 21	0.1x	—
Q1 22	0.1x	—
Q2 22	0.1x	—
Q3 22	0.0x	—
Q4 22	0.1x	—
Q1 23	0.1x	—
Q2 23	0.1x	—
Q3 23	0.1x	—
Q4 23	0.1x	—
Q1 24	0.1x	—
Q2 24	0.1x	—
Q3 24	0.1x	—
Q4 24	0.1x	—
Q1 25	0.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 21	-$62M	-$70M
Q3 21	-$25M	-$26M
Q4 21	-$35M	-$38M
Q1 22	-$73M	-$76M
Q2 22	-$73M	-$75M
Q3 22	$26M	$22M
Q4 22	-$45M	-$48M
Q1 23	-$69M	-$72M
Q2 23	-$57M	-$60M
Q3 23	-$12M	-$14M
Q4 23	-$17M	-$19M
Q1 24	-$43M	-$45M
Q2 24	-$41M	-$44M
Q3 24	-$45M	-$46M
Q4 24	-$41M	-$42M
Q1 25	-$29M	-$29M

Capital Expenditures

Quarter	CapEx
Q2 21	$8M
Q3 21	$2M
Q4 21	$3M
Q1 22	$3M
Q2 22	$2M
Q3 22	$3M
Q4 22	$3M
Q1 23	$3M
Q2 23	$3M
Q3 23	$2M
Q4 23	$2M
Q1 24	$1M
Q2 24	$3M
Q3 24	$1M
Q4 24	$1M
Q1 25	$42.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 21	+6.6%	+15.4%
Q3 21	+2.5%	+52.6%
Q4 21	+13.5%	+9.2%
Q1 22	+8.9%	+52.9%
Q2 22	+37.1%	+41.4%
Q3 22	+17.7%	+6.8%
Q4 22	-8.1%	-4.9%
Q1 23	-5.7%	+10.4%
Q2 23	-33.9%	-10.1%
Q3 23	-33.2%	-23.4%
Q4 23	-30.7%	-23.9%
Q1 24	-33.6%	-34.0%
Q2 24	-11.9%	-18.5%
Q3 24	+34.7%	-44.9%
Q4 24	-29.5%	+16.9%
Q1 25	-37.1%	-50.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 21	$10M	18.9%
Q3 21	$17M	30.6%
Q4 21	$20M	20.3%
Q1 22	$30M	47.2%
Q2 22	$29M	38.3%
Q3 22	$34M	51.3%
Q4 22	$22M	24.1%
Q1 23	$51M	84.0%
Q2 23	$24M	47.5%
Q3 23	$26M	58.9%
Q4 23	$19M	29.7%
Q1 24	$22M	53.4%
Q2 24	$19M	44.2%
Q3 24	$23M	37.6%
Q4 24	$12M	25.6%
Q1 25	$6M	22.5%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q2 21	$45M	$16M	$14M
Q3 21	$50M	$36M	$36M
Q4 21	$50M	$37M	$29M
Q1 22	$52M	$30M	$33M
Q2 22	$53M	$34M	$16M
Q3 22	$57M	$31M	$40M
Q4 22	$61M	$27M	$22M
Q1 23	$62M	$55M	$15M
Q2 23	$55M	$30M	$11M
Q3 23	$42M	$36M	$22M
Q4 23	$47M	$27M	$10M
Q1 24	$43M	$44M	$2M
Q2 24	$41M	$23M	$17M
Q3 24	$20M	$31M	$13M
Q4 24	$22M	$34M	$8M
Q1 25	$14M	$23M	$6M

Revenue Segments

Quarter	Consumer Services	Research Services
Q2 21	$44M	$11M
Q3 21	$46M	$11M
Q4 21	$84M	$17M
Q1 22	$56M	$8M
Q2 22	$57M	$19M
Q3 22	$54M	$13M
Q4 22	$81M	$11M
Q1 23	$48M	$12M
Q2 23	$49M	$3M
Q3 23	$43M	$2M
Q1 24	$39M	$126.1K

Revenue by Geography

Quarter	Canada	Other Regions	United Kingdom	United States
Q2 21	$3M	$2M	$12M	$39M
Q3 21	$3M	$1M	$11M	$42M
Q4 21	$5M	$2M	$21M	$72M
Q1 22	$3M	$1M	$12M	$48M
Q2 22	$3M	$1M	$19M	$53M
Q3 22	$3M	$1M	$16M	$47M
Q4 22	$5M	$2M	$16M	$70M
Q1 23	$2M	$1M	$14M	$43M
Q2 23	$3M	$1M	$4M	$42M
Q3 23	$2M	$1M	$2M	$39M
Q4 23	$3M	$2M	$4M	$55M
Q1 24	$2M	$990.0K	$2M	$35M
Q2 24	$2M	$1M	$2M	$39M
Q1 25	$1M	$590.0K	$1M	$22M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 20	$0	$416M	$416M
Q3 20	$289M	$0	$289M
Q4 20	$282M	$0	$282M
Q2 23	$256M	$0	$256M
Q3 23	$242M	$0	$242M
Q4 23	$218M	$0	$218M
Q1 24	$171M	$0	$171M
Q2 24	$127M	$0	$127M
Q3 24	$79M	$0	$79M
Q4 24	$38M	$0	$38M
Q1 25	$40M	$0	$40M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 21	20M	+0.1%	+0.1%
Q3 21	21M	+4.8%	+5.0%
Q4 21	22M	+2.3%	+7.4%
Q1 22	22M	+2.3%	+9.8%
Q2 22	22M	+0.8%	+10.6%
Q3 22	23M	+0.8%	+6.3%
Q4 22	23M	+0.6%	+4.5%
Q1 23	23M	+1.3%	+3.5%
Q2 23	24M	+2.7%	+5.5%
Q3 23	24M	+1.3%	+6.0%
Q4 23	24M	+1.1%	+6.5%
Q1 24	25M	+2.0%	+7.3%
Q2 24	26M	+2.9%	+7.5%
Q3 24	26M	+3.3%	+9.6%
Q4 24	26M	-2.0%	+6.3%
Q1 25	27M	+6.5%	+10.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 21	$28M	2
Q3 21	$28M	2
Q4 21	$130.9K	768
Q1 22	$84.0K	768
Q2 22	$98.5K	768
Q3 22	$87.2K	768
Q4 22	$113.2K	816
Q1 23	$74.6K	816
Q2 23	$61.3K	816
Q3 23	$54.8K	816
Q4 23	$110.0K	582
Q1 24	$69.4K	582
Q2 24	$75.7K	582
Q3 24	$103.5K	582
Q4 24	$170.4K	265
Q1 25	$95.9K	265

Revenue / Employee